皮肤与紫外线肿瘤移植风险评估计算器(SUNTRAC)在大型欧洲实体器官移植受者队列中的外部验证
该回顾性外部验证预后研究基于荷兰(1995-2016)和西班牙(2011-2021)教学医院移植中心前瞻性收集的3421例欧洲实体器官移植受者数据,评估SUNTRAC工具对皮肤癌风险的区分度和校准度。SUNTRAC将患者分为4组,各组皮肤癌风险显著不同,中危组5年皮肤癌累积发病率预测6.2%、观察7.0%,一致性指数0.72。结论支持在欧洲人群中用SUNTRAC对移植受者进行皮肤癌风险分层并识别高危患者。
要点
- SUNTRAC将实体器官移植受者分为4个皮肤癌风险组,各组风险显著不同。
- 以低危组为参照,中危组SHR 6.8,高危组SHR 15.9,极高危组SHR 54.8。
- 中危组5年皮肤癌累积发病率预测6.2%、观察7.0%,预测与实际相似。
核心结论
- 外部验证结果支持在欧洲人群中用SUNTRAC对实体器官移植受者进行皮肤癌风险分层,并识别皮肤癌高危患者,有助于优先安排和提供更好的筛查与监测。
研究设计与样本
- 回顾性外部验证预后研究,使用荷兰(1995-2016)和西班牙(2011-2021)教学医院移植中心前瞻性收集的欧洲实体器官移植受者队列数据,受者在皮肤科筛查和随访,数据分析于2021年9月至10月进行。
主要发现
- 共纳入3421例实体器官移植受者,移植时中位年龄53岁(四分位1:42;四分位3:62),2132例(62.3%)为男性。
- 随访共23213年,603例发生皮肤癌;皮肤癌诊断包括鳞状细胞癌、基底细胞癌、黑色素瘤和梅克尔细胞癌。
- 以低危组为参照,中危组SHR 6.8(95%CI 3.8-12.1;P<.001),高危组SHR 15.9(95%CI 8.9-28.4;P<.001),极高危组SHR 54.8(95%CI 29.1-102.9;P<.001),一致性指数0.72。
- 中危组5年皮肤癌累积发病率预测6.2%、观察7.0%,实际发病率与SUNTRAC预测相似。
关键数值与推荐
- SUNTRAC将患者分为4组,随访期间各组皮肤癌风险显著不同。
- 以低危组为参照,中危组SHR 6.8(95%CI 3.8-12.1;P<.001),高危组SHR 15.9(95%CI 8.9-28.4;P<.001),极高危组SHR 54.8(95%CI 29.1-102.9;P<.001)。
- 中危组5年皮肤癌累积发病率预测6.2%、观察7.0%。
- 一致性指数为0.72。
临床怎么用
- 作者认为,外部验证结果支持在欧洲人群中用SUNTRAC对实体器官移植受者进行皮肤癌风险分层并识别高危患者。
- 作者认为,这有助于优先安排和提供更好的筛查与监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) tool has been developed in the US to facilitate the identification of solid organ transplant recipients (SOTRs) at a higher risk of developing skin cancer. However, it has not yet been validated in populations other than the one used for its creation. OBJECTIVE: To provide an external validation of the SUNTRAC tool in different SOTR populations. DESIGN, SETTING, AND PARTICIPANTS: This retrospective external validation prognostic study used data from a prospectively collected cohort of European SOTRs from transplant centers at teaching hospitals in the Netherlands (1995-2016) and Spain (2011-2021). Participants were screened and followed up at dermatology departments. Data were analyzed from September to October 2021. MAIN OUTCOMES AND MEASURES: The discrimination ability of the SUNTRAC tool was assessed via a competing risk survival analysis, cumulative incidence plots, and Wolbers concordance index. Calibration of the SUNTRAC tool was assessed through comparison of projected skin cancer incidences. Skin cancer diagnoses included squamous cell carcinoma, basal cell carcinoma, melanoma, and Merkel cell carcinoma. RESULTS: A total of 3421 SOTRs (median age at transplant, 53 [quartile 1: 42; quartile 3: 62] years; 2132 [62.3%] men) were assessed, including 72 Asian patients (2.1%), 137 Black patients (4.0%), 275 Latinx patients (8.0%), 109 Middle Eastern and North African patients (3.2%), and 2828 White patients (82.7%). With a total of 23 213 years of follow-up time, 603 patients developed skin cancer. The SUNTRAC tool classified patients into 4 groups with significantly different risks of developing skin cancer during follow-up. Overall, the relative rate for developing skin cancer estimated using subdistribution hazard ratios (SHRs) and using the low-risk group as the reference group, increased according to the proposed risk group (medium-risk group: SHR, 6.8 [95% CI, 3.8-12.1]; P < .001; high-risk group: SHR, 15.9 [95% CI, 8.9-28.4]; P < .001; very-high-risk group: SHR, 54.8 [95% CI, 29.1-102.9]; P < .001), with a concordance index of 0.72. Actual skin cancer incidences were similar to those predicted by the SUNTRAC tool (5-year skin cancer cumulative incidence for medium-risk group: predicted, 6.2%; observed, 7.0%). CONCLUSIONS AND RELEVANCE: The findings of this external validation prognostic study support the use of the SUNTRAC tool in European populations for stratifying SOTRs based on their skin cancer risk and also detecting patients at a high risk of developing skin cancer. This can be helpful in prioritizing and providing better screening and surveillance for these patients.
引用
- Gómez-Tomás Á, Bouwes Bavinck JN, Genders R, et al. External Validation of the Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) in a Large European Solid Organ Transplant Recipient Cohort. JAMA Dermatol. 2023. PMID: 36416811. doi:10.1001/jamadermatol.2022.4820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。